{
    "nct_id": "NCT03389347",
    "official_title": "Individualized Treatment for Relapsed/Refractory Multiple Myeloma Based on High Throughput Drug Sensitivity and Genomics Data",
    "inclusion_criteria": "* Diagnosis of multiple myeloma or plasma cell leukemia with documented relapsed or refractory disease according to International Myeloma Working Group (IMWG) criteria, in any one of the following categories:\n\n  * 3 prior lines of therapy including an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI)\n  * Less than a very good partial response (VGPR) to initial therapy\n  * Early relapse (< 12 months) after autologous hematopoietic cell transplant (HCT) or after 1st line of therapy\n* Collection of a bone marrow, fluid or tissue sample that is expected to have enough cells to run the assay\n* Measurable disease defined by one of the following:\n\n  * Serum monoclonal protein >= 0.5 g/dL by serum protein electrophoresis (SPEP)\n  * >= 200 mg/monoclonal protein in urine on 24 hr urine protein electrophoresis (UPEP)\n  * Involved serum free light chain (FLC) >= 10 mg/dL and abnormal involved:uninvolved ratio\n  * Plasma cytomas that are palpable per exam or measurable per standard radiologic review\n  * Circulating plasma cells >= 2,000 if diagnosis of plasma cell leukemia\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3\n* Female patients of child bearing potential and non-vasectomized male patients agree to practice appropriate methods of birth control\n* Ability to understand purpose and risks of the study and provide signed and dated informed consent, and authorization to use protected health information\n* Expected survival is > 100 days\n* Adequate organ function as determined by the investigator\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Mucosal or internal bleeding, or platelet transfusion refractory\n* Any medical conditions that would impose excessive risk to the patient, or would adversely affect his/her participation in the study\n* Known active infection requiring antibiotics within 7 days of initiation of study treatment, unless considered controlled in the opinion of the investigator\n* Other malignancy with life expectancy < 1 year due to the other malignancy\n* Pregnant or breast feeding women\n* Serious psychiatric illness, alcoholism, or drug addiction\n* Human immunodeficiency virus (HIV), or active hepatitis B or C infection\n* Previous treatments for multiple myeloma (MM) within 2 weeks of initiation of study treatment\n* Prior autologous or allogeneic stem cell transplantation (SCT) within 12 weeks of initiation of study treatment\n* Prior allogeneic hematopoietic cell transplantation (HCT) with active graft versus host disease (GVHD) on therapeutic dosing of immunosuppression or prednisone > 20 mg daily equivalent\n* Prior major surgical procedure or radiation treatment within 2 weeks of initiation of study treatment (not including limited radiation used for palliation of bone pain)",
    "miscellaneous_criteria": ""
}